ProShares Ultra NASDAQ Biotechnology
19 hedge funds and large institutions have $2.12M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
2.79% less ownership
Funds ownership: 5.32% → 2.53% (-2.8%)
17% less capital invested
Capital invested by funds: $2.55M → $2.12M (-$426K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KFS
Kaizen Financial Strategies
Campbell,
California
|
+$393K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$28.1K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$888 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$74 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
-$655K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$567K |
| 3 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$534K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$381K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$7.4K |
BIB Hedge Fund Activity: Q4 2025 in Review
19 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2025, worth a combined $2.12M — down 17% from $2.55M a quarter earlier.
Fund positioning in BIB was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Kaizen Financial Strategies, opening a new position worth an estimated $393K. The largest seller was Palumbo Wealth Management, cutting an estimated $655K.
- 19 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $2.12M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2025, down 17% quarter-over-quarter.
- 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2025 was Kaizen Financial Strategies, an estimated $393K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2025 was Palumbo Wealth Management, an estimated $655K sold.
Based on aggregated 13F filings for Q4 2025.